370 related articles for article (PubMed ID: 27655642)
21. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
[TBL] [Abstract][Full Text] [Related]
22. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
[TBL] [Abstract][Full Text] [Related]
23. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
24. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
25. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis induced by trimethyltin chloride in human neuroblastoma cells SY5Y is regulated by a balance and cross-talk between NF-κB and MAPKs signaling pathways.
Qing Y; Liang Y; Du Q; Fan P; Xu H; Xu Y; Shi N
Arch Toxicol; 2013 Jul; 87(7):1273-85. PubMed ID: 23423712
[TBL] [Abstract][Full Text] [Related]
27. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
29. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
Qu Y; Wang J; Sim MS; Liu B; Giuliano A; Barsoum J; Cui X
Breast Cancer Res Treat; 2010 Jun; 121(2):311-21. PubMed ID: 19609669
[TBL] [Abstract][Full Text] [Related]
30. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Lei L; Zhang Y; Jian Q; Lei L; Lv N; Williamson RA; Chen P; Zhang D; Hu J
Exp Physiol; 2021 Feb; 106(2):438-449. PubMed ID: 33336554
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
32. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
33. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight.
Rai G; Mishra S; Suman S; Shukla Y
Phytomedicine; 2016 Mar; 23(3):233-42. PubMed ID: 26969377
[TBL] [Abstract][Full Text] [Related]
36. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Gandhi S; El-Dakdouki M; Basson MD; Walsh MF; Huang X; Vyas AK; Chaturvedi LS
J Nanosci Nanotechnol; 2015 Sep; 15(9):6413-22. PubMed ID: 26690867
[TBL] [Abstract][Full Text] [Related]
40. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
